Spots Global Cancer Trial Database for tqb2450
Every month we try and update this database with for tqb2450 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) | NCT04325763 | Stage III Non-s... | TQB2450 Anlotinib TQB2450(blank) Anlotinib(blank... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma | NCT03991975 | Advanced Acral ... | Anlotinib TQB2450 | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer | NCT04523272 | Advanced Renal ... | TQB2450 Anlotinib Sunitinib | 18 Years - 80 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | NCT05718167 | Advanced Squamo... | TQB2450 Anlotinib hydro... Tislelizumab in... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) | NCT04405505 | Triple Negative... | TQB2450 Anlotinib Paclitaxel for ... | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer | NCT03983928 | Lung Cancer | TQB2450 Anlotinib | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma | NCT04002622 | Relapsed or Ref... | TQB2450 | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA | NCT06222944 | Gastric Cancer Adenocarcinoma ... | Anlotinib TQB2450 Albumin-Bound P... | 18 Years - 75 Years | Peking University | |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer | NCT04523272 | Advanced Renal ... | TQB2450 Anlotinib Sunitinib | 18 Years - 80 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA | NCT06222944 | Gastric Cancer Adenocarcinoma ... | Anlotinib TQB2450 Albumin-Bound P... | 18 Years - 75 Years | Peking University | |
| A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma | NCT03800706 | Safety and Effe... | TQB2450 | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer | NCT03983928 | Lung Cancer | TQB2450 Anlotinib | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | NCT05718167 | Advanced Squamo... | TQB2450 Anlotinib hydro... Tislelizumab in... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer | NCT04539977 | Small-cell Lung... | TQB2450 TQB2450 | 18 Years - 75 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | NCT05718167 | Advanced Squamo... | TQB2450 Anlotinib hydro... Tislelizumab in... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients | NCT05252078 | Esophageal Squa... Esophageal Neop... Esophageal Dise... Gastrointestina... Gastrointestina... Digestive Syste... Digestive Syste... Neoplasms by Si... Neoplasms by Hi... Neoplasms, Squa... Carcinoma, Squa... | Anlotinib hydro... TQB2450 | 18 Years - | Jiangxi Provincial Cancer Hospital | |
| A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) | NCT04325763 | Stage III Non-s... | TQB2450 Anlotinib TQB2450(blank) Anlotinib(blank... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） | NCT03910127 | Non-small Cell ... | TQB2450 Anlotinib Anlotinib | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer | NCT04236362 | Gynecological C... | TQB2450 Anlotinib | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma | NCT04002622 | Relapsed or Ref... | TQB2450 | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes | NCT05608785 | Gastric Cancer Gastroesophagea... | IBI315 Oxaliplatin Capecitabine TST001 TQB2450 Anrotinib | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701) | NCT04234607 | Extensive Small... | TQB2450 Anlotinib Etoposide Carboplatin TQB2450（blank） Anlotinib（blank... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma | NCT04895345 | Nasopharyngeal ... | TQB2450 Intensity modul... | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer | NCT04306926 | Advanced Oligom... | TQB2450 SBRT | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Tolerance and Pharmacokinetics of TQB2450 | NCT03460457 | Tumor | TQB2450 | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes | NCT05608785 | Gastric Cancer Gastroesophagea... | IBI315 Oxaliplatin Capecitabine TST001 TQB2450 Anrotinib | 18 Years - 75 Years | Henan Cancer Hospital | |
| Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors | NCT03897283 | Advanced Solid ... | TQB2450 Anlotinib | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma | NCT04002622 | Relapsed or Ref... | TQB2450 | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer | NCT04574284 | Advanced Endome... | TQB2450 Anlotinib | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
